Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Many people with symptomatic Osteoarthritis (OA) report chronic joint pain, especially if those patients are older than 50 years. In Europe OA is the most common form of chronic pain condition (34%) reported and entails a high economic and social burden for society. Probiotic treatment has been shown to promote bone metabolism, reduce pain and inflammatory responses of age-related musculoskeletal disorders, including OA. Gut microbiota has been proven to be of crucial importance in maintaining human health. However, the microbiota profile changes with aging, while the loss of microbiota diversity and the alterations in the optimal composition and quantity of beneficial microbes are believed to increase the risk of many diseases. Interestingly, emerging evidence leads to the hypothesis that alterations in the gut microbiome could also be considered as possible triggering factors in the onset of musculoskeletal disorders such as OA. We hypothesize that these patients with pain-OA will demonstrate an alteration of the gut microbiota to associated with the intensity of pain.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental group | Experimental | Probiotic product plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle). |
|
| Control group | Placebo Comparator | Sham probiotical plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Experimental group | Dietary Supplement | Probiotic (Lactobacillus casei) once daily taken by 6 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from Visual analogue scale (VAS) at 6 weeks | Baseline, immediately post-intervention (6 weeks), and follow up (4 weeks) | |
| Change from Pressure Pain Thresholds (PPT) at 6 weeks | PPT will be assessed bilaterally [in the center of the anterior aspect of patella (knee) and the trochanter site (hip)] | Baseline, immediately post-intervention (6 weeks), and follow up (4 weeks) |
| Change from Inflammatory cytokines at 6 weeks | Fasting serum concentrations of interleukin (IL)-6, tumor necrosis factor (TNF)-α, soluble IL-6 receptor (IL-6sR), soluble IL-1 receptor (IL-1sR), and C-reactive protein (CRP) were measured by enzyme-linked immunosorbent assays. | Baseline, immediately post-intervention (6 weeks), and follow up (4 weeks) |
| Change from Microbiota at 6 weeks | Microbiota composition will be identified through fecal samples for total genomic DNA extraction. The bacteria belonging to Clostridium sensu stricto, Enterobacteriaceae, Escherichia coli, Bifidobacterium, Lactobacillus and yeast were dosed using quantitative PCR approach targeted on 16S rRNA gene | Baseline, immediately post-intervention (6 weeks), and follow up (4 weeks) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jorge H Villafañe, PhD | Contact | +39 3395857563 | mail@villafane.it |
| Name | Affiliation | Role |
|---|---|---|
| Jorge H Villafañe, PhD | Fondazione Don Carlo Gnocchi ETS | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| D010146 | Pain |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
Not provided
Not provided
Not provided
Not provided
Not provided
Double Blind (Subject, Outcomes Assessor)
| Control group | Dietary Supplement | Placebo of Probiotic once daily taken by 6 weeks. |
|
| Usual medical care | Other | NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks. |
|
| D009461 |
| Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D008722 | Methods |